{"url_path":"/sec/staa/10-q/2026/item-6","section_key":"item-6","section_title":"Item 6 EXHIBITS","topic":"sec","document":{"doc_type":"10-Q","doc_date":"2026-05-13","source_url":"https://www.sec.gov/Archives/edgar/data/718937/0000718937-26-000023-index.html","accession_number":"0000718937-26-000023","cik":"0000718937","ticker":"STAA","issuer_name":"STAAR SURGICAL CO","edgar_url":"https://www.sec.gov/Archives/edgar/data/718937/0000718937-26-000023-index.html","primary_entity_key":"0000718937","primary_entity_name":"STAAR SURGICAL CO"},"word_count":617,"has_tables":true,"body_markdown":"## ITEM 6. EXHIBITS\n\n##  \n\nExhibit Number\n\n \n\n \n\nDescription\n\n \n\n \n\n \n\n \n\n3.1\n\n \n\n[Amended and Restated Certificate of Incorporation](https://www.sec.gov/Archives/edgar/data/718937/000114420418022487/tv491294_def14a.htm) (incorporated by reference to Appendix 2 of the Company’s Proxy Statement on Form DEF 14A as filed with the Commission on April 26, 2018).\n\n \n\n \n\n \n\n \n\n3.2\n\n \n\n \n\n[Amended and Restated Bylaws](https://www.sec.gov/Archives/edgar/data/718937/000095017025040620/staa-ex3_1.htm) (incorporated by reference to Exhibit 3.1 to the Company’s Current Report on Form 8-K as filed with the Commission on March 17, 2025).\n\n \n\n \n\n \n\n \n\n4.1\n\n \n\n \n\n[Form of Certificate for Common Stock, par value $0.01 per share](https://www.sec.gov/Archives/edgar/data/718937/000114121803000057/staar8a1ex41.txt) (incorporated by reference to Exhibit 4.1 to Amendment No. 1 to the Company’s Registration Statement on Form 8-A/A as filed with the Commission on April 18, 2003).\n\n \n\n \n\n \n\n \n\n10.1\n\n \n\n \n\n[Cooperation Agreement dated January 14, 2026 between the Company and Broadwood Partners, L.P. (i](https://www.sec.gov/Archives/edgar/data/718937/000119312526013622/d831960dex101.htm)ncorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K as filed with the Commission on January 15, 2026).\n\n \n\n \n\n \n\n \n\n10.2\n\n \n\n \n\n[Separation and Consulting Agreement dated January 14, 2026 between the Company and Stephen C. Farrell](https://www.sec.gov/Archives/edgar/data/718937/000071893726000004/staa-ex10_30.htm) (incorporated by reference to Exhibit 10.30 to the Company’s Annual Report on Form 10-K as filed with the Commission on March 3, 2026).\n\n \n\n \n\n \n\n \n\n10.3\n\n \n\n \n\n[Interim Co-CEO Letter Agreement dated February 1, 2026 between the Company and Warren Foust](https://www.sec.gov/Archives/edgar/data/718937/000071893726000004/staa-ex10_31.htm) (incorporated by reference to Exhibit 10.31 to the Company’s Annual Report on Form 10-K as filed with the Commission on March 3, 2026).\n\n \n\n \n\n \n\n \n\n10.4\n\n \n\n \n\n[Separation Agreement dated February 4, 2026 between the Company and Nathaniel Sisitsky](https://www.sec.gov/Archives/edgar/data/718937/000071893726000004/staa-ex10_32.htm)(incorporated by reference to Exhibit 10.32 to the Company’s Annual Report on Form 10-K as filed with the Commission on March 3, 2026).\n\n \n\n \n\n \n\n \n\n10.5\n\n \n\n \n\n[Consulting Agreement dated February 4, 2026 between the Company and Nathaniel Sisitsky](https://www.sec.gov/Archives/edgar/data/718937/000071893726000004/staa-ex10_33.htm) (incorporated by reference to Exhibit 10.33 to the Company’s Annual Report on Form 10-K as filed with the Commission on March 3, 2026).\n\n \n\n \n\n \n\n \n\n31.1\n\n*\n\n \n\n[Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](staa-ex31_1.htm)\n\n \n\n \n\n \n\n \n\n31.2\n\n*\n\n \n\n[Certifications Pursuant to Rule 13a-14(a) of the Securities Exchange Act of 1934, Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.](staa-ex31_2.htm)\n\n \n\n \n\n \n\n \n\n32.1\n\n**\n\n \n\n[Certification Pursuant to 18 U.S.C. Section 1350, Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.](staa-ex32_1.htm)\n\n \n\n \n\n \n\n \n\n101\n\n*\n\n \n\nFinancial statements from the quarterly report on Form 10-Q of STAAR Surgical Company for the quarter ended April 3, 2026 formatted in Inline Extensible Business Reporting Language (iXBRL), are filed herewith and include: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Income, (iii) the Condensed Consolidated Statements of Comprehensive Income, (iv) the Condensed Consolidated Statements of Stockholders’ Equity, (v) the Condensed Consolidated Statements of Cash Flows, and (vi) the Notes to Condensed Consolidated Financial Statements tagged as blocks of text.\n\n \n\n \n\n \n\n \n\n104\n\n \n\n \n\nThe cover page from the Company’s Quarterly Report on Form 10-Q for the quarter ended April 3, 2026, has been formatted in Inline XBRL with applicable taxonomy extension information contained in Exhibit 101.\n\n \n\n \n\n \n\n \n\n \n\n*\n\n \n\n \n\nFiled herewith.\n\n \n\n \n\n \n\n \n\n**\n\n \n\n \n\nCertification furnished herewith solely to accompany this quarterly report pursuant to 18 U.S.C. Section 1350. Certification is not deemed “filed” for purposes of Section 18 of the Exchange Act or otherwise subject to the liability of that section. Such certification is not deemed to be incorporated by reference into any filing under the Securities Act or the Exchange Act except to the extent that the registrant specifically incorporates it by reference.\n\n \n\n26\n\n \n\nSIGNATURES\n\nPursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.\n\n \n\n \n\n \n\n \n\nSTAAR SURGICAL COMPANY\n\n \n\n \n\n \n\n \n\n \n\n \n\nDated:\n\n \n\nMay 13, 2026\n\nBy:\n\n \n\n/s/ DEBORAH ANDREWS\n\n \n\n \n\n \n\n \n\n \n\nDeborah Andrews\n\n \n\n \n\n \n\n \n\n \n\nInterim Co-Chief Executive Officer and Chief Financial Officer\n\n \n\n \n\n \n\n \n\n \n\n(on behalf of the Registrant and as its principal executive officer and principal financial officer)\n\n \n\n27"}